Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban Bleeding Model and Reversal with 4-Factor PCC in Healthy Subjects
NCT02047565Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of edoxaban in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (6 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Bleeding duration at Day 1 and Bleeding volume at Day 1. Started Oct 2013; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02047565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047565.